Nivolumab (nabolutumab) was approved for marketing in China in June 2018. pembrolizumab (pablizumab) was also approved for marketing in July 2018 for advanced melanoma, and clinical studies are ongoing for lung cancer.
Studies to enroll Chinese patients in Atezolizumab and Durvalumab are underway and are still some time away from launch.
Co-reviewed by: Guangdong Provincial People’s Hospital Guangdong Lung Cancer Institute Dr. Wang Zhen, deputy chief physician Dr. Kai Yin